Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Humira More Convenient for Psoriasis than Remicade: Prof. Nakagawa
March 8, 2010
- AnGes MG Obtains Patent on eNOS-Induced Angiogenesis
March 8, 2010
- Hospital Managers' Understanding of New Pricing System Essential: Korosho
March 8, 2010
- GLP-1 Agonists More Convenient than DPP-4 Inhibitors: Prof Kadowaki
March 8, 2010
- Paltac to Be Listed on TSE, OSE
March 8, 2010
- NEW PRODUCTS
March 8, 2010
- UBC Opens Its Own Office in Tokyo
March 8, 2010
- 9 Products, Including Pfizer's Lyrica, Recommended for Approval
March 8, 2010
- Daiichi Sankyo to Embark on Generics Business in Japan
March 8, 2010
- BMKK to Break from Long-Listed Drugs: Mr Wright
March 8, 2010
- GRU to Focus on PMDA in 2nd Round of Screening
March 8, 2010
- Surgery-Related Societies to Create Common Database
March 8, 2010
- Takeda to Shore Up Lifestyle Diseases Area in Japan with New Products
March 8, 2010
- Astellas Licenses Isavuconazole from Basilea
March 8, 2010
- Biogen Idec Aims to Become Leading Company for MS: President Ozaki
March 8, 2010
- “Open Innovation”Essential for Drug Discovery: Dr Sakata of Shionogi
March 8, 2010
- Astellas Begins Tender Offer to Acquire OSI Pharmaceuticals
March 8, 2010
- South Korea Has Advanced Clinical Trial Infrastructures: JPMA Press Tour
March 8, 2010
- Nippon Shinyaku Props Up Marketing Structure for PAH Products
March 8, 2010
- Gov't Should Invest More in R&D: Prof. Taniguchi
March 8, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…